1. Immunology and Inflammation

Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

  1. Mariano Maio
  2. Joaquina Barros
  3. Marine Joly
  4. Zoi Vahlas
  5. José Luis Marín Franco
  6. Melanie Genoula
  7. Sarah C Monard
  8. María Belén Vecchione
  9. Federico Fuentes
  10. Virginia Gonzalez Polo
  11. María Florencia Quiroga
  12. Mónica Vermeulen
  13. Thien-Phong Vu Manh
  14. Rafael J Argüello
  15. Sandra Inwentarz
  16. Rosa Musella
  17. Lorena Ciallella
  18. Pablo González Montaner
  19. Domingo Palmero
  20. Geanncarlo Lugo Villarino
  21. María del Carmen Sasiain
  22. Olivier Neyrolles
  23. Christel Vérollet
  24. Luciana Balboa  Is a corresponding author
  1. Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Argentina
  2. International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina / International Research Project Toulouse, France
  3. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Universidad de Buenos Aires, Argentina
  4. Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France
  5. Aix Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, France
  6. Instituto Prof. Dr. Raúl Vaccarezza and Hospital de Infecciosas Dr. F.J. Muñiz, Argentina
https://doi.org/10.7554/eLife.89319.4
Share this article
Cite this article
  1. Mariano Maio
  2. Joaquina Barros
  3. Marine Joly
  4. Zoi Vahlas
  5. José Luis Marín Franco
  6. Melanie Genoula
  7. Sarah C Monard
  8. María Belén Vecchione
  9. Federico Fuentes
  10. Virginia Gonzalez Polo
  11. María Florencia Quiroga
  12. Mónica Vermeulen
  13. Thien-Phong Vu Manh
  14. Rafael J Argüello
  15. Sandra Inwentarz
  16. Rosa Musella
  17. Lorena Ciallella
  18. Pablo González Montaner
  19. Domingo Palmero
  20. Geanncarlo Lugo Villarino
  21. María del Carmen Sasiain
  22. Olivier Neyrolles
  23. Christel Vérollet
  24. Luciana Balboa
(2024)
Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis
eLife 12:RP89319.
https://doi.org/10.7554/eLife.89319.4
  2. Download BibTeX
  3. Download .RIS
10 figures, 3 tables and 1 additional file

Figures

Figure 1
Download asset Open asset
Mycobacterium tuberculosis (Mtb) rewires the metabolic network of monocyte-derived dendritic cells (Mo-DCs).

Mo-DCs were stimulated with viable or irradiated Mtb (iMtb) at two multiplicities of infection (1 or 2 Mtb per DC) for 24 hr. Glycolysis was measured as (A) lactate release in culture supernatants …

Figure 2 with 1 supplement
Download asset Open asset
Mycobacterium tuberculosis (Mtb) skews dendritic cell (DC) metabolism toward glycolysis.

Monocyte-derived DCs (Mo-DCs) were stimulated with irradiated Mtb (iMtb) or infected with Mtb expressing red fluorescent protein (Mtb-RFP, panel C). (A) Representative histograms showing the …

Figure 2—figure supplement 1
Download asset Open asset
Contribution of the fatty acid oxidation (FAO) to dendritic cell (DC) metabolism in response to irradiated Mycobacterium tuberculosis (iMtb).

Relative contributions of mitochondrial and FAO dependences to overall DC metabolism analyzed with SCENITH in DCs exposed or not to iMtb (N = 6). Paired t-test (***p<0.001) as depicted by lines. The …

Figure 3 with 1 supplement
Download asset Open asset
Mycobacterium tuberculosis (Mtb) triggers glycolysis through TLR2 ligation in monocyte-derived dendritic cells (Mo-DCs).

Mo-DCs were stimulated with irradiated Mtb (iMtb) in the presence of neutralizing antibodies against either TLR2 (aTLR2), TLR4 (aTLR4), or their respective isotype controls. (A) Lactate release as …

Figure 3—figure supplement 1
Download asset Open asset
TLR2 ligation triggers glycolysis in monocyte-derived dendritic cells (Mo-DCs).

(A, B) Mo-DCs were stimulated or not with LPS in the presence of neutralizing antibodies against either TLR2 (aTLR2) or TLR4 (aTLR4). (A) Lactate release measured in supernatant (N = 6). (B) Glucose …

Figure 4 with 3 supplements
Download asset Open asset
HIF1A is required for dendritic cell (DC) maturation upon irradiated Mycobacterium tuberculosis (iMtb) stimulation but not for CD4+ T lymphocyte polarization.

(A–C) Monocyte-derived DCs (Mo-DCs) were stimulated with iMtb in the presence or absence of the HIF1A inhibitor PX-478 (PX). (A) Metabolic flux analysis showing quantification of mitochondrial ATP …

Figure 4—figure supplement 1
Download asset Open asset
HIF1A activity is required to trigger the glycolytic pathway in irradiated Mycobacterium tuberculosis (iMtb)-stimulated dendritic cells (DCs).

Monocyte-derived DCs (Mo-DCs) were stimulated with iMtb in the presence of PX-478 (PX, A–C) or echinomycin (Ech, D–F), both HIF1A inhibitors. (A, D) Lactate release measured in supernatant (N = …

Figure 4—figure supplement 2
Download asset Open asset
HIF1A is required to adopt a mature phenotype in irradiated Mycobacterium tuberculosis (iMtb)-stimulated dendritic cells (DCs).

Monocyte-derived DCs (Mo-DCs) were stimulated with iMtb in the presence or not of echinomycin (Ech), an HIF1A inhibitor. Mean fluorescence intensity (MFI) of CD83, CD86, and PD-L1 (N = 10). Two-way …

Figure 4—figure supplement 3
Download asset Open asset
Gating strategy to define CD4+ T cells in response to Mycobacterium tuberculosis (Mtb).

Monocytes from PPD+ healthy donors were differentiated toward dendritic cells (DCs), challenged or not with irradiated Mtb (iMtb) in the presence or not of PX-478, and co-cultured with autologous …

Figure 5 with 1 supplement
Download asset Open asset
HIF1A-mediated-glycolysis is required to trigger migratory activity in irradiated Mycobacterium tuberculosis (iMtb)-stimulated dendritic cells (DCs).

Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. (A) Lactate release as measured in supernatants …

Figure 5—figure supplement 1
Download asset Open asset
Glycolysis is required to trigger the migratory activity in irradiated Mycobacterium tuberculosis (iMtb)-stimulated dendritic cells (DCs).

(A, B) Monocyte-derived DCs (Mo-DCs) were treated or not with the glycolysis inhibitor GSK2837808A and stimulated with iMtb. (A) Lactate release (N = 5). (B) Chemotactic activity toward CCL21 (N = …

Figure 6 with 1 supplement
Download asset Open asset
Stabilization of HIF1A promotes migration of tolerogenic dendritic cells (DCs) and monocyte-derived DCs (Mo-DCs) from tuberculosis (TB) patients.

Tolerogenic Mo-DCs were generated by dexamethasone (Dx) treatment and were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb) in the presence or absence of HIF1A activator …

Figure 6—figure supplement 1
Download asset Open asset
Profile of tolerogenic dendritic cells (DCs) induced by dexamethasone (Dx).

Tolerogenic monocyte-derived DCs (Mo-DCs) were generated in the presence or not of Dx and stimulated with iMtb. (A) Mean fluorescence intensity (MFI) of CD83, CD86, and PD-L1 (N = 9). The data are …

Figure 7 with 1 supplement
Download asset Open asset
CD16+ monocytes from tuberculosis (TB) patients show increased glycolytic capacity.

(A) Monocytes from TB patients or healthy subjects (HS) were isolated and cultured with IL-4 and GM-CSF for 24 hr. Accumulation of lactate in culture supernatants were measured at 1 and 24 hr of …

Figure 7—figure supplement 1
Download asset Open asset
Association between baseline glycolytic status of monocytes and the severity of lung disease.

The glycolytic capacity was assessed in monocyte subsets from tuberculosis (TB) patients with bilateral versus unilateral disease, reflecting the extent of disease (upper panels), or with cavitary …

Figure 8 with 2 supplements
Download asset Open asset
HIF1A activation in CD16+ monocytes from tuberculosis (TB) patients leads to dendritic cells (DCs) with poor migration capacity.

(A) Ex vivo determination of HIF1A expression by monocytes from healthy subjects (HS) or TB patients (TB) for each monocyte subset (CD14+CD16-, CD14+CD16+, and CD14dimCD16+) (N = 6). (B, C) …

Figure 8—figure supplement 1
Download asset Open asset
Impact of premature activation of HIF1A in monocytes on the generated dendritic cells (DCs).

Monocytes from healthy subjects (HS) were treated with dimethyloxalylglycine (DMOG) during the first 24 hr of differentiation with IL-4/GM-CSF (earlyDMOG) and removed afterward. On day 6 of …

Figure 8—figure supplement 2
Download asset Open asset
Dual role of the glycolysis/HIF1A axis on dendritic cell (DC) migration in tuberculosis (TB).

Working model showing that DCs enhance their glycolytic activity upon encountering M. tuberculosis, facilitating their migration to lymph nodes. Conversely, in CD16+ monocyte populations of patients …

Author response image 1
Download asset Open asset
Correlation analysis between the baseline glycolytic capacity and the time since treatment onset for each monocyte subset (CD14+CD16-, CD14+CD16+ and CD14dimCD16+, N = 11).

Linear regression lines are shown. Spearman’s rank test. The data are represented as scatter plots with each circle representing a single individual.

Author response image 2
Download asset Open asset
Gene enrichment analysis for glycolytic genes on the pairwise comparisons of each monocyte subset (CD14+CD16-, CD14+CD16+ and CD14dimCD16+) from patients with active TB pre-treatment vs patients with active TB (TB) undergoing treatment for 2 months.

Comparisons with a p-value of less than 0.05 and an FDR value of less than 0.25 are considered significantly different.

Tables

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
AntibodyAnti-human TLR2BioLegendCat# 309717
AntibodyAnti-human TLR4BioLegendCat# 312813
AntibodyAnti-human CD1aeBioscienceRRID:AB_467039
AntibodyAnti-human DC-SIGNR&D SystemCat# MAB161
AntibodyAnti-human CD14BD BiosciencesCat# 557154
AntibodyAnti-human CD86BioLegendCat# 374216
AntibodyAnti-human CD83eBioscienceCat# 14-0839-82
AntibodyAnti-human CD274 (B7-H1, PD-L1)BD PharmingenCat# 557924
AntibodyAnti-human Glut1R&D SystemCat# MAB1418
AntibodyAnti-human HIF1ABioLegendCat# 359704
AntibodyAnti-human CD4BioLegendCat# 357402
AntibodyAnti-human CXCR3BioLegendCat# 353719
AntibodyAnti-human CCR4BD BiosciencesCat# 560726
AntibodyAnti-human CCR6BD BiosciencesCat# 560619
AntibodyAnti-human CD3BioLegendCat# 300317
AntibodyAnti-human CD16BioLegendCat# 302008
AntibodyAnti-mouse CD11cBD PharmingenCat# 561044
Biological sample (Mycobacterium tuberculosis)M. tuberculosis H37RvN/AN/A
Biological sample (M. tuberculosis)Tuberculosis γ-irradiated H37RvBEI ResourceCat# NR-49098
Biological samplePatients-derived bloodHospital F.J.Muñiz (Buenos Aires, Argentina)N/A
Biological sampleBuffy coats from healthy donorsCentro Regional de Hemoterapia Garrahan (Buenos Aires, Argentina)N/A
Biological sampleBlood from PPD+ healthy donorsN/AN/A
Peptide, recombinant proteinRecombinant human GM-CSFPeprotechCat# 300-03
Peptide, recombinant proteinRecombinant human IL-4BioLegendCat# 430307
Peptide, recombinant proteinRecombinant mouse GM-CSFBioLegendCat# 576304
Peptide, recombinant proteinRecombinant mouse IL-4BioLegendCat# 574302
Chemical compound, drugLipopolysaccharides from Escherichia coli O127:B8Sigma-AldrichCat# 93572-42-0
Chemical compound, drugDexamethasoneSidusCat# 229197-1
Chemical compound, drugPX-478 2HClSelleck ChemicalsCat# S7612
Chemical compound, drugDMOGBertin TechnologiesCat# 300-02
Chemical compound, drugGSK2837808ACayman ChemicalCat# 1445879-21-9
Chemical compound, drugEchinomycinCayman ChemicalCat# 512-64-1
Chemical compound, drugSodium oxamateCayman ChemicalCat# 565-73-1
Peptide, recombinant proteinRecombinant Human Exodus-2 (CCL21)PeprotechCat# 300-35A
Chemical compound, drugCollagen from calf skinSigma-AldrichCat# C9791-10MG
Commercial assay or kitLactate KitWienerCat# 1999795
Commercial assay or kitGlicemia Enzimática AA KitWienerCat# 1009803
Commercial assay or kitPerm2 solutionBD BiosciencesCat# 340973
Commercial assay or kitTrizol reagentThermo Fisher ScientificCat# 15596026
Commercial assay or kitMitoSpy Green FMBioLegendCat# 424805
Commercial assay or kitTNF alpha Human ELISA KiteBiosciencesCat# BMS223-4
Commercial assay or kitIL-10 Human ELISA KiteBiosciencesCat# BMS215-2
Commercial assay or kitIL-17A Human ELISA KiteBiosciencesCat# 88-7176-22
Commercial assay or kitIFN gamma Human ELISA KiteBiosciencesCat# BMS228
Commercial assay or kitZombie Violet Fixable Viability KitBioLegendCat# 423113
Commercial assay or kitSCENITHGifted by Rafael ArgüelloN/A
Sequence-based reagentPrimer: EEF1A1 Fwd: TCGGGCAAGTCCACCACTACMarín Franco et al., 2020N/A
Sequence-based reagentPrimer: EEF1A1 Rev: CCAAGACCCAGGCATACTTGAMarín Franco et al., 2020N/A
Sequence-based reagentPrimer: HIF1A Fwd: ACTAGCCGAGGAAGAACTATGAAMarín Franco et al., 2020N/A
Sequence-based reagentPrimer: HIF1A Rev: TACCCACACTGAGGTTGGTTAMarín Franco et al., 2020N/A
Sequence-based reagentPrimer: LDHA Fwd: TGGGAGTTCACCCATTAAGCMarín Franco et al., 2020N/A
Sequence-based reagentPrimer: LDHA Rev: AGCACTCTCAACCACCTGCTMarín Franco et al., 2020N/A
Software, algorithmImageJImageJhttps://imagej.nih.gov/ij/
Software, algorithmPrism (v5)GraphPadhttps://www.graphpad.com/
Software, algorithmFlowJo 7.6.5TreeStarhttps://www.flowjo.com/
Software, algorithmFCS Express V3DeNovo Softwarehttps://www.denovosoftware.com/
Software, algorithmSeahorse WaveAgilenthttps://www.agilent.com/
Software, algorithmCFX MaestroBio-Radhttps://www.bio-rad.com/
Software, algorithmMetamorphMolecular Deviceshttps://www.moleculardevices.com/
Table 1
Demographic and clinical characteristics of tuberculosis (TB) patients.
Age, years (range)36 (19–67)
Gender, % (number/total)M, 81% (31/38)
F, 19% (7/38)
Nationality, % (number/total)Argentina, 76.31% (29/38)
Bolivia, 15.78% (6/38)
Paraguay, 2.63% (1/38)
Peru, 5.26% (2/38)
TB disease localization, % (number/total)Pulmonary, 94% (36/38)
Pulmonary + extrapulmonary, 6% (2/38)
AFB* in sputum, % (number/total)3+, 21% (8/38)
2+, 13% (5/38)
1+, 52% (20/38)
-, 13% (5/38)
Leukocyte count, mean ± SEM, cell/µl8483 ± 509
Lymphocyte mean ± SEM, %19 ± 2
Monocyte mean ± SEM, %7 ± 0.5
  1. *

    Acid-fast-bacilli (AFB) in sputum: -, 1+, 2+, 3+ are defined according to the International Union Against Tuberculosis and Lung Disease (IUATLD)/World Health Organization (WHO) quantification scale.

Author response table 1
-iMtb-iMtb
Exp 112,730,11,4510,30
Exp 24,77,36,6813,43
Exp 316,7725,676,7418,98
Exp 42,3421,330,123,02
Exp 59,8311,466,03
Exp 612251,0020,70

Additional files

MDAR checklist
https://cdn.elifesciences.org/articles/89319/elife-89319-mdarchecklist1-v1.docx

Download links